Reaction-Based Enumeration, Active Learning, and Free
Energy Calculations To Rapidly Explore Synthetically Tractable Chemical
Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors
posted on 2019-08-22, 13:35authored byKyle D. Konze, Pieter H. Bos, Markus K. Dahlgren, Karl Leswing, Ivan Tubert-Brohman, Andrea Bortolato, Braxton Robbason, Robert Abel, Sathesh Bhat
The hit-to-lead and lead optimization
processes usually involve
the design, synthesis, and profiling of thousands of analogs prior
to clinical candidate nomination. A hit finding campaign may begin
with a virtual screen that explores millions of compounds, if not
more. However, this scale of computational profiling is not frequently
performed in the hit-to-lead or lead optimization phases of drug discovery.
This is likely due to the lack of appropriate computational tools
to generate synthetically tractable lead-like compounds in silico,
and a lack of computational methods to accurately profile compounds
prospectively on a large scale. Recent advances in computational power
and methods provide the ability to profile much larger libraries of
ligands than previously possible. Herein, we report a new computational
technique, referred to as “PathFinder”, that uses retrosynthetic
analysis followed by combinatorial synthesis to generate novel compounds
in synthetically accessible chemical space. In this work, the integration
of PathFinder-driven compound generation, cloud-based FEP simulations,
and active learning are used to rapidly optimize R-groups, and generate
new cores for inhibitors of cyclin-dependent kinase 2 (CDK2). Using
this approach, we explored >300 000 ideas, performed >5000
FEP simulations, and identified >100 ligands with a predicted IC<sub>50</sub> < 100 nM, including four unique cores. To our knowledge,
this is the largest set of FEP calculations disclosed in the literature
to date. The rapid turnaround time, and scale of chemical exploration,
suggests that this is a useful approach to accelerate the discovery
of novel chemical matter in drug discovery campaigns.